Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid by Yuen, RMF et al.
Title
Prognostic Factors for Transplant-Free Survival and Validation
of Prognostic Models in Chinese Patients with Primary Biliary
Cholangitis Receiving Ursodeoxycholic Acid
Author(s) Cheung, KS; Seto, WKW; Fung, JYY; Lai, CL; Yuen, RMF
Citation Clinical and Translational Gastroenterology, 2017, v. 8 n. 6, p.e100:1-10
Issued Date 2017
URL http://hdl.handle.net/10722/246564
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Prognostic Factors for Transplant-Free Survival and
Validation of Prognostic Models in Chinese Patients
with Primary Biliary Cholangitis Receiving
Ursodeoxycholic Acid
Ka-Shing Cheung, MBBS, MPH1, Wai-Kay Seto, MD1,2, James Fung, MD1,2, Ching-Lung Lai, MD1,2 and Man-Fung Yuen, MD, PhD1,2
OBJECTIVES: We aimed to validate the prognostic models for primary biliary cholangitis (PBC) in Chinese patients receiving
ursodeoxycholic acid (UCDA), and to compare their performances in predicting the long-term survival.
METHODS: Chinese patients with PBC from a tertiary center were identified via electronic search of hospital medical registry. Risk
factors associated with adverse events (liver transplantation or death from liver-related causes including hepatocellular carcinoma
(HCC) and liver decompensation) were determined. Transplant-free survival was defined as survival free of liver-related death or
transplantation.
RESULTS: Of the 144 patients, 41 (28.5%) had baseline cirrhosis. The median age at diagnosis was 57.8 years. During a median
follow-up of 7.0 years, 40 patients died (21 liver-related; 19 non-liver-related), 12 developed HCC, and 10 underwent
transplantations. The 5-, 10-, and 15-year transplant-free survival probabilities were 91.0%, 78.1%, and 58.9%, respectively.
Independent risk factors for adverse events were increasing age (hazard ratio (HR) 1.05), cirrhosis (HR 8.53), and suboptimal
treatment response (HR 3.06). Aspartate aminotransferase/platelet ratio index at 1 year (APRI-r1) in combination with treatment
response optimized the risk stratification. The performances of the GLOBE, UK-PBC scores, Rotterdam criteria, and APRI-r1 were
comparable in predicting adverse events. The area under receiver operating curves within 5, 10, and 15 years were as follows—
GLOBE score: 0.83, 0.85, and 0.85, respectively; UK-PBC score: 0.89, 0.83, and 0.79, respectively; Rotterdam criteria: 0.82, 0.76, and
0.80, respectively; APRI-r1: 0.80, 0.83, and 0.77, respectively.
CONCLUSIONS: The UK-PBC, GLOBE scores, Rotterdam criteria, and APRI-r1 had good and comparable prognostic prediction
values for Chinese PBC patients receiving UCDA.
Clinical and Translational Gastroenterology (2017) 8, e100; doi:10.1038/ctg.2017.23; published online 22 June 2017
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic liver
disease due to an immune-mediated damage on the small-
sized biliary ducts leading to progressive ductal destruction
and loss.1 Cirrhosis is one of the major risk factors for poor
prognosis, posing a higher risk of hepatocellular carcinoma
(HCC) development and death.2
Without treatment, patients with PBC are estimated to have
5-, 10-, and 15-year transplant-free survival rates of 79%, 59%,
and 32%, respectively.3 Currently, ursodeoxycholic acid (UDCA)
is the global standard of treatment that has consistently shown
to be beneficial in delaying histologic progression, reducing
cirrhotic complications, and liver transplantations, as well as
improving long-term survival.4–7 In fact, among those who have
an adequate response to UDCA, the survival is comparable to
that of age- and sex-matched healthy subjects, while the
disease progression is faster for suboptimal responders.5
Around 35% of PBC patients do not have an optimal
response to UDCA.8 Therefore, a number of prognostic
models exist to define biochemical response to UCDA,
including the Rotterdam criteria,9 Barcelona criteria,5 Paris I
criteria,8 Paris II criteria,10 and Toronto criteria.11 They have
been shown to be able to stratify the risks of developing
adverse outcomes including cirrhosis, HCC, and mortality.
However, these prognostic models are based on treatment
response only. Newer models, the UK-PBC score and GLOBE
score, have been developed by including other prognostic
factors such as age, platelet count,12 aspartate aminotrans-
ferase (AST). The AST/platelet ratio index (APRI) at baseline
and at 1 year (APRI-r1) were also found to be able to optimize
risk stratification.12–14 The UK-PBC score and GLOBE score
were found to outperform the other models based on treat-
ment response only. Application of APRI-r1 to all biochemical
criteria has also been shown to improve the predictive
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performances.15 As such, the net reclassification indexes
were similar for APRI in combination with other biochemical
criteria and GLOBE score (20–35%).
There is a recent study conducted by Yang et al.16 validating
various prognostic models in the Chinese population. How-
ever, this study has a short duration of follow-up (a mean of
36±16 months), and therefore the performances of these
models to predict adverse outcomes can only be determined
at the time point of 5 years. In addition, since only seven
patients had liver transplantations or liver-related deaths,
the study end point was defined as development of cirrhotic
complications, while the UK-PBC and PBC scores are
developed to predict adverse outcomes of liver transplantation
and death.
The aim of our study was to validate various prognostic
models and to compare their performances in predicting the
long-term survival in Chinese patients with PBC.
METHODS
Data sources and study population. All patients with PBC
who were followed up in the Hepatology Clinic of Queen Mary
Hospital between January 2000 and October 2015 were
recruited. Queen Mary Hospital is one of the major public
hospitals in Hong Kong with a population of ~ 7.3 million, and
is also a tertiary referral center.
Our departmental practice was to prescribe UCDA to all
PBC patients. Patients prescribed with UCDA in Queen Mary
Hospital between 2000 and 2015 were first identified by
electronic search of the hospital medical registry. Non-PBC
cases were subsequently excluded by reviewing both case
notes and electronic medical records of these patients.
Patients who were non-Chinese or who received UCDA for
o1 year were also excluded. Other exclusion criteria included
the overlap syndrome (as defined by the Paris Study Group
Criteria)17 and other concomitant liver diseases such as
chronic hepatitis B virus infection, chronic hepatitis C virus
infection, alcoholic liver disease, steatohepatitis, and Wilson’s
disease. The search and identification of PBC patients in our
study are illustrated in Figure 1.
The study protocol was approved by the Institutional Review
Board, the University of Hong Kong and West Cluster of
Hospital Authority, Hong Kong.
Outcomes and covariates
Diagnosis of PBC. PBC was diagnosed when two out of
three criteria were satisfied: (1) cholestatic liver biochemistry
with raised alkaline phosphatase (ALP) at least 1.5 times the
upper limit of normal (ULN); (2) anti-mitochondrial antibody
(AMA) positivity; (3) compatible histological features “non-
suppurative destructive cholangitis with destruction of inter-
lobular biliary ducts”.2
For cases with liver biopsies, histologic staging was
classified according to the staging system proposed by
Ludwig et al.18 Stage 1 is characterized by inflammation and
fibrosis limited to the portal triads. Stage 2 involves the
extension of inflammation and fibrosis to the periportal areas.
Stage 3 is defined by bridging fibrosis, whereas stage 4 is
defined by the presence of cirrhosis.
Diagnosis of early PBC. The Paris II criteria were specifically
developed to predict adverse outcomes in patients with early-
stage disease in the study by Corpechot et al.10 Both
histological (Ludwig’s stages 1 to 2) and biochemical criteria
(normal bilirubin and albumin levels at baseline) are shown to
be valid in defining early PBC.
Surveillance and diagnosis of adverse outcomes. Patients
were followed up every 3 to 6 months with regular monitoring
of platelet count, transaminases, ALP, γ-glutamyl transferase
(GGT), bilirubin, albumin, prothrombin time (PT), intern-
ational normalized ratio, α-fetoprotein, and creatinine.
Patients requiring HCC surveillance as suggested by
standard guidelines19 were advised to have ultrasonography
of the liver at 6-monthly intervals.
HCC was diagnosed by histology or typical radiological
features (arterial enhancement and venous washout by
triphasic computed tomography scan or contrast magnetic
resonance imaging). Cirrhosis was diagnosed by imaging
(ultrasonography/computed tomography/magnetic reso-
nance imaging showing small, nodular liver, or features of
portal hypertension namely splenomegaly, varices, and
ascites), transient elastography with a fibrosis score 416.9
kPa20 or clinical features including thrombocytopenia,
coagulopathy, gastroesophageal varices, ascites, and hepatic
encephalopathy.
Adverse events included liver transplantation and/or death
from liver-related causes, including HCC and liver decom-
pensation as defined by variceal bleeding, spontaneous
bacterial peritonitis, hepatorenal syndrome, and/or hepatic
encephalopathy. Transplant-free survival was defined as
survival free of liver-related death or liver transplantation.13
For the GLOBE score, adverse events were defined as liver
transplantation and/or all-cause mortality.14 Patients were
censored at the date of latest follow-up or date of non-liver-
related death. The duration of follow-up referred to the period
of observation from the date of diagnosis to the censored date.
Figure 1 Flowchart illustrating case search and identification. HBV, hepatitis B
virus; PBC, primary biliary cholangitis; UCDA, ursodeoxycholic acid.
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Suboptimal response to treatment. In the initial analysis of
the risk factors for adverse events, suboptimal response to
UCDA was identified by using the Paris I criteria, defined as
ALP more than three times the ULN, AST more than two times
the ULN, or bilirubin more than 1 mg/dl. The Paris I criteria
were used because they were shown in previous studies to
outperform other treatment response criteria.9,12,21,22 The
descriptions of other prognostic risk models are shown in
Supplementary Table 1. As proposed by Trivedi et al.,12 APRI-
r1 in combination with treatment response criteria enables the
classification of PBC patients into low-risk (biochemical
response with APRI-r1 ≤0.54), intermediate risk (suboptimal
biochemical response with APRI-r1 ≤0.54, or biochemical
response with APRI-r1 40.54), and high risk (suboptimal
biochemical response with APRI-r1 40.54).
Statistical analyses. All statistical analyses were performed
using R version 3.2.3 (A language and environment for
statistical computing, Vienna, Austria, ISBN 3-900051-07-0,
URL http://www.R-project.org) statistical software. Continu-
ous variables were expressed as median and interquartile
range. The Mann–Whitney U-test was used to compare
continuous variables of two groups. The χ2 test or Fisher’s
exact test when appropriate was applied for comparing
categorical variables. The Cox proportional hazards model
was used to identify variables that were associated with
adverse events. To deal with missing data in the Cox model,
multiple imputation was used to construct 50 complete data
sets by imputing the missing variables.23 The Kaplan–Meier
method was used to analyze the adverse outcomes, and
statistical significance was determined by log-rank test. The
receiver operating curve was generated by plotting ‘sensitivity’
against ‘1 - specificity’ at different values. The performances of
various prognostic models were expressed in terms of area
under receiver operating curve (AUROC), with the 95%
confidence interval (95% CI) being derived from bootstrapping
by sampling with replacement from the original sample and
repeating the process by 1,000 times. A two-sided P value of
o0.05 was used to define statistical significance.
Results
Patient characteristics. A total of 144 patients with PBC
were identified. The baseline demographics, laboratory
results, and histology staging are shown in Table 1a. One
hundred and twenty-seven patients (88.2%) were female, and
the median age at diagnosis was 57.8 years (interquartile
range: 48.7–71.5 years). Forty-one patients (28.5%) had
cirrhosis before treatment commencement. For patients with
liver biopsy reports available for review (n= 52), 44.2% had
stage 3 or 4 disease. The median dose of UCDA that patients
received was 750 mg. The proportions of patients with
suboptimal response to treatment are listed in Table 1b,
ranging from 33.3 to 42.4% according to different criteria.
Table 1c shows the proportions of patients with suboptimal
Table 1a Baseline characteristics of the study cohort (n= 144)
Variable Whole cohort
(n= 144)
Patients with adverse
events (n=30)
Patients without adverse
events (n= 114)
P value
Age (years) 57.8 (48.7–71.5) 59.7 (45.3–71.0) 57.6 (49.0–72.1) 0.678
Female sex, n (%) 127 (88.2%) 24 (80.0%) 103 (90.4%) 0.118
Duration of follow-up (years) 7.0 (3.6–10.6) 7.4 (4.5–11.8) 7.0 (3.3–10.4) 0.376
Ursodeoxycholic acid (mg) 750 (750–750) 750 (750–750) 750 (750–750) 0.491
Suboptimal treatment response (Paris I criteria) 52 (36.1%) 21 (70.0%) 31 (27.2%) o0.001
Diabetes, n (%) 29 (20.1%) 6 (20.0%) 23 (20.2%) 0.983
Smoking, n (%)a 13 (9.5%) 4 (14.3%) 9 (8.3%) 0.303
Alcohol, n (%)a 17 (13.7%) 2 (6.9%) 15 (13.4%) 0.525
Cirrhosis, n (%) 41 (28.5%) 21 (70.0%) 20 (17.5%) o0.001
Histological stages 3 and 4, n (%)b 23 (44.2%) 12 (75.0%) 11 (30.6%) 0.006
Platelet (x109/l)a 216 (152–262) 135 (90–202) 234 (182–269) o0.001
Creatinine (μmol/l)a 69 (60–82) 75 (62–87) 68 (60–81) 0.210
Albumin (g/l)a 40 (36–42) 35 (31–40) 40 (38–43) o0.001
Bilirubin (μmol/l)a 14 (10–26) 30 (19–55) 13 (9–22) o0.001
ALP (U/l) 284 (196–484) 332 (224–486) 267 (194–483) 0.376
ALT (U/l)a 74 (54–130) 88 (54–139) 73 (54–126) 0.540
AST (U/l)a 68 (51–115) 89 (62–125) 65 (40–108) 0.079
GGT (U/l)a 517 (256–771) 619 (457–776) 436 (219–765) 0.134
PT (s) 11.3 (10.5–11.7) 11.7 (11.4–12.8) 11.1 (10.5–11.5) o0.001
AMA positivity 119 (82.6%) 22 (73.3%) 97 (85.1%) 0.130
Globulin (mg/dl)a 41 (37–46) 44 (38–50) 41 (37–45) 0.161
IgM (mg/dl)a 363 (250–502) 462 (289–593) 356 (240–444) 0.044
Mayo risk score 4.7 (3.8–5.5) 5.5 (4.8–6.6) 4.4 (3.7–5.2) o0.001
MELD score 6 (6–8) 7 (6–9) 6 (6–6) 0.005
CPS 5 (5–6) 6 (5–8) 5 (5–6) o0.001
CP class B/C 29 (20.1%) 12 (40.0%) 17 (14.9%) o0.001
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, anti-mitochondrial antibody; AST, aspartate aminotransferase; CPS, Child–Pugh score;
GGT, γ-glutamyl transferase; IgM, immunoglobulin M; INR, international normalized ratio; MELD, model for end-stage liver disease; PT, prothrombin time.
Adverse events were defined as liver transplantation or liver-related death.
All continuous variables are expressed in median (interquartile range).
aMissing data: smoking (7), alcohol (3), platelet (10), creatinine (1), albumin (2), bilirubin (2), ALT (2), AST (2), GGT (2), globulin (6), and IgM (20).
bSixty-two patients had liver biopsies performed with reports available for review in 52.
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treatment response according to different age strata. The
rates of treatment response did not differ significantly across
different age strata by using the Rotterdam, Barcelona, or
Paris I criteria. However, when the Toronto criteria were used,
younger patients had significantly lower rates of treatment
response. None of the patients in the present cohort received
fibric acid derivatives.
The median follow-up was 7.0 years (interquartile range:
3.6–10.6 years), and the total follow-up was 1,151 patient-
years. Forty patients died (liver-related deaths: 21; non-liver-
related deaths: 19), 12 patients developed HCC, and 10
patients underwent liver transplantations.
Sixty-two patients had liver biopsies performed with reports
available for review in 52. Using the Paris II criteria, only 29
patients had early PBC according to the histological criteria,
whereas 52 patients had early-stage disease according to the
biochemical criteria. As a result of the relatively small sample
size and number of events (n= 4) in this subgroup of patients,
Cox regression analysis and determination of AUROCs were
not performed for the Paris II criteria.
Risk factors for adverse events. Table 2a shows the
association between various factors and adverse events.
On univariate analysis, male sex, presence of cirrhosis, lower
platelet count, lower serum albumin, higher serum bilirubin,
longer PT, higher serum globulin and immunoglobulin M
(IgM) on presentation, and suboptimal response to UCDA
(as defined by the Paris I criteria) were significant risk factors
for liver transplantation and/or liver-related death. Baseline
serum transaminases, ALP, and GGTwere not significant risk
factors. All significant risk factors on univariate analysis were
further assessed by multivariate analysis. Risk factors that
remained to be significant were older age (hazard ratio (HR)
1.05; 95% CI: 1.02–1.08), presence of cirrhosis (HR 8.53;
95% CI: 2.80–25.96) and suboptimal treatment response
using the Paris I criteria (HR 3.21; 95% CI: 1.24–8.33).
Table 2b shows the HR of suboptimal response as defined by
different prognostic models. Multivariate analysis (in which
statistically significant factors in Table 2a were included) was
performed separately for each prognostic model. Suboptimal
treatment response was a significant risk factor when the
Rotterdam criteria (HR 4.05; 95% CI: 1.39–11.84), Barcelona
criteria (HR 3.25; 95% CI: 1.27–8.34), or Paris I criteria
(HR 3.21; 95% CI: 1.24–8.33) were adopted, but not for the
Toronto criteria.
Patients were classified into low risk, intermediate risk,
and high risk according to the biochemical response and
APRI-r1 as mentioned in the previous section.12 High-risk
patients (suboptimal biochemical response with APRI-r1
40.54) had the poorest prognosis compared with low-risk
and intermediate-risk patients, with consistent findings using
the Paris I, Rotterdam, and Toronto criteria (Table 2c).
Survival analysis. The overall 5-, 10-, and 15-year trans-
plant-free survival rates were 91.0% (95% CI: 85.8–96.5),
78.1% (95% CI: 69.6–87.5), and 58.9% (95% CI: 46.1–75.4),
respectively (Figure 2a).
Transplant-free survival was significantly better for patients
without baseline cirrhosis than for thosewith cirrhosis (log rank
Po0.001; Figure 2b). Among patients without baseline
cirrhosis, the 5-, 10-, and 15-year transplant-free survival
rates were 97.1% (95% CI: 93.3–100), 93.5% (95% CI:
87.4–99.3), and 86.4% (95% CI: 75.8–98.4). Among patients
with baseline cirrhosis, the 5-, 10-, and 15-year transplant-free
survival rates were 75.3% (95% CI: 61.7–91.9), 44.9%
(95% CI: 29.4–68.6), and 15.7% (95% CI: 4.8–51.3).
Survival was also significantly better for patients who
showed response to UCDA according to different treatment
response criteria (all log rank Po0.05) (Figure 3a–c), except
for the Toronto criteria (log rank P=0.159). The classification
of patients into low risk, intermediate risk, and high risk
according to the biochemical response and APRI-r1 further
stratified the risks of transplant-free survival, regardless of
which treatment response criteria was being used (all log rank
Po0.05) (Figure 4a–d).
Validation of various prognostic models. The perfor-
mances of the GLOBE and UK-PBC scores were comparable
in predicting adverse events in our cohort, with an overlap
of the 95% CIs. For the GLOBE score, the AUROCs for
adverse events within 5, 10, and 15 years were 0.83 (95% CI:
0.74–0.90), 0.85 (95% CI: 0.75–0.92) and 0.85 (95% CI:
Table 1b Number of patients with suboptimal treatment response according to
different criteria
Criteria Number of patientswith suboptimal
treatment response (%)
Rotterdam criteria 61 (42.4%)
Barcelona criteria 48 (33.3%)
Paris I criteria 52 (36.1%)
Toronto criteriaa 50 (38.8%)
aFifteen patients had missing data on the ALP level at 2 years after treatment.
Table 1c Number and proportions of patients with suboptimal treatment response according to different criteria among various age strata
Ageo40 years
(n= 7)
Age 40–49.9 years
(n= 35)
Age 50–59.9 years
(n=36)
Age 60–69.9
years (n=25)
Age ≥70 years
(n= 41)
P value
Rotterdam criteria 4 (57.1%) 11 (31.4%) 11 (30.6%) 11 (44.0%) 24 (58.5%) 0.063
Barcelona criteria 2 (28.6%) 7 (20%) 11 (30.6%) 14 (56.0%) 14 (34.1%) 0.070
Paris I criteria 4 (57.1%) 14 (40%) 13 (36.1%) 8 (32.0%) 13 (31.7%) 0.719
Toronto criteria 6 (85.7%) 19 (57.6%)a 11 (35.5%)b 6 (27.3%)c 8 (22.2%)d 0.002
aTwo patients had missing data on the ALP level at 2 years after treatment.
bFive patients had missing data on the ALP level at 2 years after treatment.
cThree patients had missing data on the ALP level at 2 years after treatment.
dFive patients had missing data on the ALP level at 2 years after treatment.
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0.73–0.95), respectively. For the UK-PBC score, the
AUROCs for adverse events within 5, 10, and 15 years were
0.89 (95% CI: 0.77–0.98), 0.83 (95% CI: 0.73–0.91), and
0.79 (95% CI: 0.65–0.91), respectively. In comparison, the
AUROCs by using other prognostic models within 5, 10, and
15 years were as follows: (Rotterdam=0.82, 0.76, 0.80;
Barcelona= 0.69, 0.60, 0.68; Paris I=0.72, 0.70, 0.67;
Toronto= 0.55, 0.52, 0.51; APRI= 0.61, 0.69, 0.40; APRI-
r1= 0.80, 0.83, 0.77). With regard to non-PBC-specific
scores, the AUROCs within 5, 10, and 15 years were 0.67,
0.69, 0.71 for model for end-stage liver disease score and
0.84, 0.69, 0.70 for Child–Pugh score (CPS).
Table 3 summarizes the predictive performances of various
models. Among the criteria based on treatment response
only, the sensitivity and negative predictive value (NPV) were
highest using the Rotterdam criteria. Values of sensitivity,
specificity, positive predictive value (PPV), and NPV were not
available for the UK-PBC, GLOBE, APRI, APRI-r1, MELD, and
CPS as these scores were on a continuous scale.
DISCUSSION
The present study recruited 144 Chinese PBC patients who
had received UDCA for at least 1 year. The median age at
diagnosis was 57.8 years in our cohort, which was similar to
that described in studies from other Asian countries (including
Taiwan, Singapore, and South Korea), ranging from 55.6 to
57.4 years.24–26 With the mean age of diagnosis of 54.5 years
in the western population,3 Asian patients appear to be diag-
nosed with PBC at a slightly older age. Females accounted for
the majority of our cohort (88%), and 43% of our patients had
stage 3 or 4 disease at the time of diagnosis. The female
preponderance and proportion of patients with advanced
histologic disease are similar to those reported in the West.2,8
Table 2a HRs and 95% CIs for the association between variables and adverse events (liver-related death or liver transplantation)
Variables Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (years) 1.02 1.00–1.05 0.079 1.05 1.02–1.08 o0.001
Male 3.26 1.28–8.33 0.014 0.81 0.25–2.61 0.721
Smoking 2.23 0.76–6.59 0.146
Alcohol 0.73 0.17–3.12 0.674
Diabetes mellitus 0.78 0.31–1.92 0.583
Cirrhosis 9.64 4.23–22.00 o0.001 8.53 2.80–25.96 o0.001
Platelet (x109/l) 0.99 0.986–0.997 0.001 1.00 0.99–1.01 0.755
Creatinine (μmol/l) 1.01 0.98–1.03 0.600
Albumin (g/l) 0.83 0.77–0.89 o0.001 0.95 0.85–1.08 0.452
Bilirubin (μmol/l)a 1.02 1.01–1.03 0.001
ALP (U/l) 1.00 0.997–1.001 0.291
ALT (U/l) 1.00 0.992–1.002 0.245
AST ( U/l) 1.00 0.995–1.005 0.863
GGT (U/l) 1.00 0.999–1.001 0.697
PT (s) 1.31 1.05–1.63 0.018 1.04 0.74–1.45 0.829
AMA positivity 0.70 0.31–1.60 0.400
Globulin (mg/dl) 1.06 1.01–1.11 0.023 1.04 0.97–1.12 0.298
IgM (mg/dl) 1.001 1.000–1.002 0.035 1.00 0.999–1.001 0.281
Suboptimal treatment response (Paris I criteria)a 4.55 2.01–10.28 o0.001 3.21 1.24–8.33 0.017
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, anti-mitochondrial antibody; AST, aspartate aminotransferase; 95% CI, 95% confidence interval;
GGT, γ-glutamyl transferase; HR, hazard ratio; IgM, immunoglobulin M; INR, international normalized ratio; PT, prothrombin time.
P valueso0.05 are highlighted in bold.
aIn the multivariate analyses, bilirubin was not included as this variable was already included in the Paris I criteria.
Table 2b HRs and 95% CIs for the association between suboptimal treatment response (as defined by various prognostic models) and adverse events (liver-related
death or liver transplantation)
Criteria Univariate analysis aMultivariate analysis
HR 95% CI P value HR 95% CI P value
Rotterdam 9.07 3.44–23.88 o0.001 4.05 1.39–11.84 0.011
Barcelona 3.75 1.72–8.20 o0.001 3.25 1.27–8.34 0.014
Paris I 4.55 2.01–10.28 o0.001 3.21 1.24–8.33 0.017
Toronto 1.54 0.72–3.32 0.265 1.62 0.57–4.57 0.362
95% CI, 95% confidence interval; HR, hazard ratio.
P valueso0.05 are highlighted in bold.
aThe adjusted HR for suboptimal response was derived by multivariate analysis with other significant variables in Table 2a (age, male sex, cirrhosis, platelet, albumin,
bilirubin, prothrombin time, globulin and immunoglobulin M) included. Separate multivariate analysis was performed for each criteria in defining suboptimal response.
In the multivariate analyses, bilirubin was not included for the Paris I criteria, whereas both bilirubin and albumin were not included for the Rotterdam criteria, as these
variables were already included in the criteria.
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The treatment response rate was also comparable, ~ 33–42%
according to different criteria. In addition, the survival rates of
our cohort were similar to those reported in a meta-analysis,3
with the 5-, 10-, and 15-year transplant-free survival rates
being 91%, 78%, and 59% vs. 88%, 77%, and 63%, respec-
tively. Overall, the characteristics of our cohort of Chinese
patients were similar to those of the Western population.
Our study validated different prognostic models and
compared their performances in Chinese PBC patients
receiving UDCA. In our study, both the recently developed
Table 2c Prediction of adverse events (liver-related death or liver transplantation) by suboptimal treatment response in combination with APRI-r1
Criteria Univariate analysis aMultivariate analysis
HR 95% CI P value HR 95% CI P value
Rotterdamb
Low risk Reference — — Reference — —
Intermediate risk 1.59 0.27–9.51 0.613 1.05 0.16–7.07 0.956
High risk 11.80 2.76–50.36 o0.001 5.30 1.03–27.34 0.046
Barcelonab
Low risk Reference — — Reference — —
Intermediate risk 5.94 0.75–47.01 0.091 2.29 0.24–21.82 0.473
High risk 22.33 2.91–171.26 0.003 8.38 0.96–73.17 0.055
Paris I b
Low risk Reference — — Reference — —
Intermediate risk 3.96 0.77–20.46 0.100 1.94 0.32–11.55 0.469
High risk 10.02 2.33–43.10 0.002 5.48 1.09–27.60 0.039
Toronto
Low risk Reference — — Reference — —
Intermediate risk 9.58 1.20–76.88 0.033 9.73 0.84–112.80 0.069
High risk 12.60 1.66–95.68 0.014 18.67 1.49–234.17 0.023
APRI-r1, AST/platelet ratio index at 1 year; 95% CI, 95% confidence interval; HR, hazard ratio.
P valueso0.05 are highlighted in bold.
aThe adjusted HR for suboptimal response was derived by multivariate analysis with other significant variables in Table 2a (age, male sex, cirrhosis, platelet, albumin,
bilirubin, prothrombin time, globulin and immunoglobulin M) included. Separate multivariate analysis was performed for each criteria in defining suboptimal response.
In the multivariate analyses, bilirubin was not included for the Paris I criteria, whereas both bilirubin and albumin were not included for the Rotterdam criteria, as these
variables were already included in the criteria.
bMissing data: 6 (Paris I, Rotterdam and Barcelona criteria in combination with APRI-r1), 20 (Toronto criteria in combination with APRI-r1).
Figure 2 Baseline cirrhosis was associated with poorer transplant-free survival. (a) Kaplan–Meier survival plot for overall survival of the whole cohort. (b) Kaplan–Meier
survival plot stratified by baseline cirrhosis.
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models (the GLOBE and UK-PBC scores) had better
predictability (AUROCs close to or 40.80 for predicting
adverse events within 5, 10, and 15 years) than other
criteria based only on treatment response (except for the
Rotterdam criteria), the results of which were consistent with
studies of the western population.13,14 There are several
possible reasons to explain this. First, a number of important
independent factors are included in the GLOBE and UK-PBC
scores, e.g., age,21 bilirubin,3,27 ALP,5,8,10 albumin,28 and platelet
count,12 while the other criteria are based only on treatment
response, and therefore cirrhosis may not be taken into
consideration. Second, dichotomization of continuous variables
in previous criteria will affect the robustness of the model.29
The overall performance (in terms of AUROC) of theGLOBE
score in the validation cohort from the Global PBC Study
Group was 0.82,14 while that of the UK-PBC score in the
Figure 3 Suboptimal treatment response was associated with poorer transplant-free survival. (a) Kaplan–Meier survival plot stratified by treatment response (Rotterdam
criteria). (b) Kaplan–Meier survival plot stratified by treatment response (Barcelona criteria). (c) Kaplan–Meier survival plot stratified by treatment response (Paris I criteria).
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validation cohort from the UK-PBC Research Cohort was as
follows: AUROCs of 0.96, 0.95, and 0.94 within 5, 10, and 15
years, respectively.13 APRI-r1 was another prognostic model
with a good performance (AUROUC of ~ 0.80)12
Our study showed that the performances of these two newly
developed models were comparable in terms of predicting
adverse events in theChinese population, as evidenced by the
overlapping of the 95% CIs across different periods. The
performances of the GLOBE score were similar in the western
and Chinese patients, while the UK-PBC score performed
better in the western population. However, these results
should be interpreted with caution as the number of patients
recruited in our study was less than the Global PBC Study
Group and UK-PBC Research Cohort.
Figure 4 Treatment response criteria in combination with APRI-r1 further stratified risks of transplant-free survival. (a) Kaplan–Meier survival plot stratified by treatment
response (Rotterdam criteria) and APRI-r1. (b) Kaplan–Meier survival plot stratified by treatment response (Barcelona criteria) and APRI-r1. (c) Kaplan–Meier survival plot
stratified by treatment response (Paris I criteria) and APRI-r1. (d) Kaplan–Meier survival plot stratified by treatment response (Toronto criteria) and APRI-r1. APRI-r1, AST/platelet
ratio index at 1-year; low risk (biochemical response with APRI-r1≤ 0.54), intermediate risk (suboptimal biochemical response with APRI-r1≤ 0.54; or biochemical response with
APRI-r140.54) and high risk (suboptimal biochemical response with APRI-r140.54).
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As for the other prognostic models, the Rotterdam criteria
and the APRI-r1 had overall better performances for prediction
of adverse events, followed by the Paris I criteria and the
Barcelona criteria, whereas the Toronto criteria did not have
satisfactory performance. A previous study also showed that
the Rotterdam and the Paris I criteria had better performance
among criteria based on treatment response.14
All of these criteria had high NPV (490% at 5 years,475%
at 10 years) but low PPV (o23% at 5 years, o53% at
10 years) in predicting adverse events. Overall, with increasing
years, the sensitivity and NPV decreased, while the specificity
and PPV increased. These results suggest that treatment
response criteria, particularly the Rotterdam and the Paris I
criteria, were accurate at recognizing patients with good
prognosis.
One of the strengths of our study is the case recruitment
process, in which cases were identified via electronic search
of the hospital medical registry, with subsequent verification
by reviewing case notes and electronic medical records. This
ensures the completeness of case recruitment. Moreover, the
relatively long duration of follow-up (a median duration of
7 years with the longest duration up to 26 years) allowed for
moremeaningful comparison of the hazards of adverse events
with regard to different predictive variables, despite the long
lag time for the development of adverse events from diagnosis
that was typical of PBC.
There are some limitations of our study. First, the sample
size was relatively small. However, the results obtained from
this study appear to be valid, as evidenced by the shared
patient characteristics between our cohort and other studies,
as well as the consistency in terms of the performance of
various prognostic models. Second, as our hospital is a
tertiary center in the territory, the study cohort may represent a
selected group of patients (which explains the relatively large
number of events including HCC, transplantation and deaths
in this study). Therefore, the findings of this study may not be
applicable to all Asian PBC patients. Third, we could not
ascertain whether UCDA was prescribed by a weight-based
approach at a dose of 13–15 mg/kg per day,30 because data of
the baseline body weight were missing in some patients in this
retrospective study. However, the survival rates of our cohort
were similar to those reported in a meta-analysis,3 indicating
that the bias related to theUCDAdosewasminimal. In fact, the
patients in the UK-PBC Research Cohort also received a
lower median dose of 12 mg/kg per day (interquartile range:
9–14 mg/kg per day).13
In conclusion, our study validated the usefulness of the
GLOBE, UK-PBC scores, Rotterdam criteria and APRI-r1 in
predicting the prognosis of long-term survival in Chinese PBC
patients treated with UDCA. These prognostic models can
potentially stratify the risks of individual patients, hence
identifying those who require closer follow-up and at need of
alternative therapies, such as obeticholic acid.31 Further
studies with larger sample sizes are warranted to confirm
our findings.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Primary biliary cholangitis (PBC) can lead to hepatocellular
carcinoma (HCC) and death.
✓ Studies on prognostic models predicting the long-term
survival in PBC patients are lacking in Chinese population.
WHAT IS NEW HERE
✓ UK-PBC and GLOBE scores had good prognostic
prediction values among Chinese PBC patients
receiving ursodeoxycholic acid (UCDA).
✓ Rotterdam criteria and APRI-r1 also had satisfactory
prognostic prediction values.
✓ The 5-, 10- and 15-year transplant-free survival rates were
similar between Chinese and western patients.
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